🔗 Share this article

An underground market for unlicensed slimming medications is being driven by social media fitness personalities and sellers on messaging platforms, according to new investigations.

Experimental Drug Gaining Traction Online

The experimental drug, which is still in research studies, is being advertised by online personalities for its supposed fat-burning properties. Followers are encouraged to message these profiles privately for source information, while also obtaining promotional offers.

Active Trade on Social Networks

Additionally, a robust trade exists on messaging services, where groups with numerous of members share comparison photos, injection guides and claims of next-day UK delivery. Sellers promote the substance there before redirecting buyers to other platforms for purchases.

Learning About Retatrutide

Retatrutide is an experimental injectable created by US drugmaker Eli Lilly. The treatment affects three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies suggest it could assist individuals reduce up to 25% of their total weight. Referred to as the “triple G”, the drug is being promoted online as the successor to Ozempic.

Medical Professionals Express Worries

However, doctors and pharmacists have warned that the distribution of what is still an unlicensed medication in the UK is a cause for concern and could lead to users administering products of unknown origin.

Some professionals stated the demand for the experimental drug could be connected to the increasing cost of licensed slimming products such as Mounjaro.

Regulatory Status and Enforcement

Selling the unapproved drug on TikTok or Telegram is illegal in the United Kingdom, as it is an unlicensed medication that cannot be promoted or distributed for human use under the British medical regulations.

Some content creators try to sidestep the regulations by referring to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a controlled drug, but advertising and supply can still breach medicines, advertising, and customer regulations, potentially leading to penalties, prosecution or prison.

Service Reaction and Material Elimination

Based on the social media company, the service has removed problematic content and banned related keywords and query recommendations. The organization said it was dedicated to maintaining the platform secure and allocating resources in strengthening compliance measures.

Digital Trading Operations

Research also discovered groups with up to nine thousand participants selling retatrutide using the platform's integrated discovery tool, which operates like a online catalog. Entering “retatrutide” instantly displays groups with numerous of users, populated with photos of slimming results, positive reviews and detailed guides for mixing or injecting at home.

After moments of joining one group, a seller shared contact information, where most purchases occur. The vendor provided an guidebook and guaranteed shipping within two days. When questioned whether the substance was authentic, one vendor said: “You can’t be sure.” Another provided a photo of a supposed testing documentation. None asked about weight, health issues or past usage.

Product Details and Costs

Within these communities, posts show black plastic packages with Royal Mail stickers, stating to contain new batches. One message stated: “It took eight of us to load them this morning.”

Customers can select between dry substance containers, mixed at residence with sterile water, or pre-filled injectors usually priced at £160 for 20mg. When questioned how long a pen should last, vendors give contradictory answers varying between a several days to “depends on your body”.

Platform Oversight and Security Measures

A representative for the messaging service said it actively monitored harmful material on its service including material that promoted the “misuse of controlled medications”. The company noted that it eliminated “millions of pieces of harmful content each day”.

Healthcare Expert Warnings

“People are injecting substances they can’t verify. Even if the science behind retatrutide is sound, these online versions may not include what they claim,” said Jason Murphy, the head of pharmaceutical services at a pharmacy service.

A medical professional of an online medical service linked the surge in interest to recent price rises for approved weight-loss medications such as Mounjaro. “With costs rising, patients are turning to online platforms. But fake injections are extremely dangerous. You can’t be certain what’s inside or whether the conditions they were produced in was sterile,” she said.

Her staff has already seen patients injured by self-injection from unverified suppliers. “We understand the frustration, but buying from Telegram or communication platforms is gambling with your health,” said the doctor. “These substances could be impure or incorrectly dosed.”

Producer Position

A spokesperson from the pharmaceutical company stated the substance was in third stage clinical trials and had not been reviewed or authorized by any regulatory agency globally. “Therefore at this point no one can market [it] for human use,” they said, adding that any item “misleadingly claiming itself as a Lilly investigational substance not yet approved … may subject patients to potentially significant medical dangers”.